You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Collision-Avoidance Radar for Small UAS
SBC: UAVradars LLC Topic: A202In the near future unmanned aircraft systems (UAS) will be utilized for many societal and commercial applications. However, the hurdle of operation safety in the form of avoiding airborne collisions must first be overcome. UAVradars LLC is proposing a small, lightweight, and low-power radar system designed specifically to give small UAS (< 55 lbs) airborne collision-avoidance sensory capability. ...
SBIR Phase II 2016 National Aeronautics and Space Administration -
Pre-concentrator for Capture of Trace Fluorocarbons
SBC: XPLOSAFE LLC Topic: 90108While fluorocarbons are released in relatively small amounts, they can have half-lives in the atmosphere as long as 50,000 years. However, they have extremely high global warming potential relative to other greenhouse gases, so that even small atmospheric concentrations can have large effect on global temperatures. For this reason, monitoring atmospheric concentrations of these compounds, identify ...
SBIR Phase I 2016 Department of CommerceNational Institute of Standards and Technology -
Novel immunotherapy strategy for treatment of pancreatic cancer
SBC: Oncotab, Inc. Topic: NCIDESCRIPTION provided by applicant Pancreatic cancer has the worst prognosis of all cancers and is the fourth leading cause of cancer related deaths in the United States Patients usually present with advanced disease making curative attempts difficult Surgery is the only curative therapy since radiotherapy and chemotherapy remain largely ineffective coupled with undesirable side effects Desp ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Orally Bioavailable Gadolinium Chelators for Preventing and Ameliorating Toxicity Due to MRI Contrast Agents
SBC: Capture Pharmaceuticals, Inc. Topic: 102DESCRIPTION provided by applicant Capture Pharmaceuticals Inc is developing a drug called C E initially intended for treatment of individuals who have been contaminated by radioactive actinide elements following a nuclear terrorism event Because of the similarities between actinides and lanthanides it is expected that C E will also be effective in removing gadolinium Gd a lanthanide in ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Delivery of pathogen trapping antibodies for vaginal protection
SBC: MUCOMMUNE, LLC Topic: NIAIDDESCRIPTION provided by applicant Despite immense efforts in behavioral interventions to promote safer sexual practices sexually transmitted infections STIs continue to be a pandemic worldwide Unfortunately there are no effective vaccines or microbicides for the majority of STIs A pathogen specific safe effective and discreet vaginal microbicide that does not require daily or sex associ ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Small Molecule Antibiotic Potentiators for Drug-Resistant Bacteria
SBC: AGILE SCIENCES, INC. Topic: NIAIDDESCRIPTION provided by applicant An estimated two million Americans suffer from infections caused by multi drug resistant MDR bacteria resulting in a substantial impact on patientsandapos lives and an extraordinary economic burden Due to the arsenal of antibiotic resistance mechanisms that these bacteria present traditional antibiotic therapies are often ineffective New strategies that u ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
CellRaft Array for Screening and Isolation of Highly Effective Cytotoxic T Cells
SBC: CELL MICROSYSTEMS INC Topic: NIAIDPROJECT SUMMARY Cell Microsystems Inc is an early stage biotechnology company whose mission is the commercialization of a novel cost effective platform enabling the identification and efficient isolation of viable cells based on morphologic and fluorescence signatures as well as characteristics that change over time The CellRaft technology is based on a unique cell array recently developed ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Development of an Osteoinductive Spinal Fusion Implant for Enhanced Fusion Rates
SBC: EVOKE MEDICAL LLC Topic: NIAMSDESCRIPTION provided by applicant The objective of this Phase I STTR research is to develop and test osteoinductive lumbar spinal fusion implant prototypes made using materials technology developments discovered by the PI at the University of Kansas In preliminary work lower impedance piezoelectric composite materials that generate power for direct current DC electrical stimulation applica ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
New Class of Bright Sharp Tunable Near Infrared Fluorophores for Flow Cytometry
SBC: Nirvana Sciences, Inc. Topic: RDESCRIPTION provided by applicant Polychromatic flow cytometry FC is one of the most powerful analytical techniques routinely used by both basic research and clinical diagnostics laboratories for the immunological categorization of cells Dyes used for FC typically exhibit broad fluorescent emission bands with full width at half maximum fwhm values of nm This limits the maximum numbe ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Human nasal epithelial organoids as a non-invasive, personalized model for predicting effectiveness of CFTR modulators in cystic fibrosis patients
SBC: Path BioAnalytics, Inc. Topic: ABCDESCRIPTION provided by applicant The discovery of the single gene CFTR cause of cystic fibrosis CF has been transformational focusing treatment on modulator drugs that restore function of the CFTR gene product CFTR andquot correctorsandquot enhance transport of mutant protein to the cell membrane and CFTR andquot potentiatesandquot activate mutant protein that does get to the membrane ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health